EIF3A and Burkitt lymphoma: Furthermore, targeting the HLH motif in EIF3A could be used in conjunction with drugs that target parallel pathways, for example doxorubicin, a drug thought to inhibit transcription by targeting DNA topoisomerases [49], that is commonly used in the treatment of Burkitt’s lymphoma.